• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Controlled Substances: Handling Red Flags
Clinical Update

Controlled Substances: Handling Red Flags

October 3, 2023
Jesse Koskey, MD.
From The Carlat Psychiatry Report
Issue Links: Editorial Information | PDF of Issue

Jesse Koskey, MD. Associate Clinical Professor, Department of Psychiatry and Behavioral Sciences, UC Davis Health.Dr. Koskey has no financial relationships with companies related to this material.

Your college-age patient leaves you a voicemail: “I know you just refilled my Adderall, and I’m really sorry about this, but I accidentally spilled it down the sink.” They leave their pharmacy information and let you know that they have a “huge exam” in two days and “would appreciate an immediate refill.”

Is this an innocent request, or has a Trojan horse of misuse or diversion entered the doctor-patient relationship? Are you annoyed? Anxious? And how does your reaction change if this patient has other “red flags” for substance misuse?

In this article, I’ll review data regarding prescription misuse (ie, use outside of prescribed directions) and diversion (ie, medications getting into the hands of those they’re not prescribed to). I’ll focus on stimulants and benzodiazepines and cover best practices for prescribing scheduled medications, including policies to guide your response to scenarios like the one above.

Stimulants

ADHD is a risk factor for substance use disorders (SUDs), but stimulant therapy can reduce the likelihood of substance use in ADHD (Quinn PD et al, Am J Psychiatry 2017;174(9):877–885). That said, patients who misuse stimulants are more likely to use alcohol and other substances, and as many as 13% of patients who misuse stimulants have met criteria for an SUD. White and Hispanic college-age males with comorbid SUDs are the most likely to misuse or divert stimulants (Clemow DB and Walker DJ, Postgrad Med 2014;126(5):64–81). In one self-report, 8% of 9,100 college students reported a history of misusing stimulants—more than those who reported a legitimate prescribed use. Over half of college students who are prescribed stimulants report being solicited for diversion. Amphetamines are misused and diverted about four times more often than methylphenidates, and animal models confirm that amphetamines have more potent and rewarding dopaminergic effects (Clemow and Walker, 2014).

Most people who misuse stimulants do so to improve their concentration at school or work, but this may be a false hope. Studies in normal subjects yield mixed results, with some showing worse sleep and impaired next-day concentration after taking a stimulant (Tselha T et al, Behav Brain Res 2019;370:111940).

Up to 20% of the general adult population presenting for an ADHD evaluation may exaggerate symptoms with the goal of obtaining a stimulant prescription, and some studies have reported that this number is as high as 50% for college students. Getting an academic edge through medications, netting better campus accommodations as a result of an ADHD diagnosis, and desiring to misuse or sell medications are common motivations for malingering (Clemow and Walker, 2014).

Benzodiazepines

As with stimulants, white college-age adults with SUDs are the population most likely to misuse benzodiazepines (Votaw VR et al, Drug Alcohol Depend 2019;200:95–114). Misuse is often motivated by symptoms rather than recreation. Seventy-five percent of national survey respondents who admitted to misusing prescription tranquilizers reported doing so to treat anxiety or sleep (www.tinyurl.com/yyn2s662). Most of this misuse (69%) involved alprazolam, likely due to its rapid onset of action and unique propensity to increase striatal dopamine (Ait-Daoud N et al, J Addict Med 2018;12(1):4–10). After alprazolam, other drugs that rank high for misuse are clonazepam, diazepam, and lorazepam (Votaw et al, 2019).

Diverted benzodiazepines may only be one degree removed from your office: 20% of adolescents and adults with a benzodiazepine prescription reported diverting it to others. 80% of those who have reported misusing benzodiazepines said that they obtained diverted meds from a friend or family member with a prescription (Votaw et al, 2019).

Red flags

Warning signs for misuse or diversion include claims of lost or stolen medications, demands for immediate attention, and requests for specific medications. People may claim exaggerated, vague, or “textbook” symptoms, decline workups, and refuse permission to obtain prior medical records or collateral, which might include stating that they’re unavailable (https://apps.deadiversion.usdoj.gov/guidance; also see our “Red Flags for Rx Misuse” table on page 3).

As you evaluate red flags, keep in mind that implicit biases often cause us to treat some individuals differently. Implicit association testing of 300 psychiatrists, residents, fellows, and medical students, for example, revealed a significant link between Black faces and the concept of noncompliance (Tobon AL et al, Acad Psychiatry 2021;45(1):23–33). A universally applied, clearly communicated policy for starting and refilling controlled substances helps minimize the consequences of our implicit biases. Your policy should be discussed with patients and signed with the written treatment agreements that precede your first visit or first prescription.

Your controlled substance policy should include the standard conversation you have when starting any medication (for example, patient expectations for medications, likely outcomes, potential risks, and alternatives). The Carlat Report has a template policy at www.tinyurl.com/2n6zv6cs. As you adapt this template to your practice or craft your own, be sure to stipulate which red flags will cause you to stop or limit refills, how often you will provide an early refill and under what conditions, when you will require scheduled or random urine drug screens, and how often you will require follow-up appointments. Most states require pharmacists to log controlled prescriptions in a central database, and your policy should describe how you will use the state prescription monitoring program.

There is no algorithm for handling red flags. Talk with the patient (and collaterals, if needed) about your concerns, and refer the patient to your agreed-on policy as a guide for the next steps. Check your state’s prescription drug monitoring database, switch to e-prescribing, and consider whether a urine drug screen would be helpful. If you’re going to provide an early refill, you may limit it to just enough pills to get the patient to your next appointment.

TCPR_Oct2023_Table_RedFlags.pngIf you have confirmed that misuse or diversion is present, assess for an SUD and offer treatment if one is present. Stimulants can be stopped immediately, as the main withdrawal symptom is a non-dangerous fatigue. For benzodiazepines, initiate a taper to prevent seizures, and refer for inpatient detox if the patient has risk factors such as epilepsy, significant medical illness, a history of withdrawal complications, or comorbid SUDs such as alcohol or opioid use disorders.

CARLAT VERDICT

Controlled medications require extra assessment and stricter prescribing practices. When prescribing controls, watch for red flags and have a policy that you apply fairly and equally to all. Offer treat- ment for SUDs when they arise.


General Psychiatry Clinical Update
KEYWORDS benzodiazepines stimulants substance use disorder
    Jesse Koskey, MD.

    Powering Up the Brain: tDCS for ADHD?

    More from this author
    www.thecarlatreport.com
    Issue Date: October 3, 2023
    SUBSCRIBE NOW
    Table Of Contents
    Learning Objectives, Sleep, TCPR, October 2023
    Controlled Substances: Handling Red Flags
    Sleep Apnea in Psychiatry
    Pets and Your Psychiatric Practice
    Do Personality Traits Impact Antidepressant Efficacy?
    DBT for Borderline Personality Disorder: Is Half the “Dose” Effective?
    CME Post-Test, Sleep, TCPR, October 2023
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.